Stockscreener 앱 받기
2.20
0.00%
0.00
전일 마감가:
$2.20
열려 있는:
$2.19
하루 거래량:
692.54K
Relative Volume:
0.38
시가총액:
$219.55M
수익:
-
순이익/손실:
$-299.80M
주가수익비율:
-0.7746
EPS:
-2.84
순현금흐름:
$-217.49M
1주 성능:
+2.33%
1개월 성능:
-20.00%
6개월 성능:
-66.05%
1년 성능:
-56.18%
1일 변동 폭
$2.17
$2.23
1주일 범위
$2.104
$2.3189
52주 변동 폭
$1.845
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
명칭
Acelyrin Inc
전화
805-456-4393
주소
4149 LIBERTY CANYON RD., AGOURA HILLS
SLRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.20 | 219.55M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-09-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 개시 | H.C. Wainwright | Buy |
| 2023-05-30 | 개시 | Jefferies | Buy |
| 2023-05-30 | 개시 | Morgan Stanley | Overweight |
| 2023-05-30 | 개시 | Piper Sandler | Overweight |
| 2023-05-30 | 개시 | TD Cowen | Outperform |
모두보기
Acelyrin Inc 주식(SLRN)의 최신 뉴스
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - TradingView
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Indo-Asian News Service - Indo-Asian News Service (IANS)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN, TURN, BHLB, MHLD - TradingView
Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease - MSN
TANG CAPITAL MANAGEMENT LLC Increases Stake in Acelyrin Inc - GuruFocus.com
ACELYRIN Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Insider Stock Sales Shake Up ACELYRIN, INC. - TipRanks
Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock By Investing.com - Investing.com South Africa
Acelyrin CEO Kim Mina sells $49,353 in company stock By Investing.com - Investing.com Canada
Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock - Investing.com
Acelyrin CEO Kim Mina sells $49,353 in company stock - Investing.com
ACELYRIN Executives Sell Shares to Cover Tax Obligations - TradingView
Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock - Investing.com India
Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock By Investing.com - Investing.com Australia
ALUMIS INC. SEC 10-K Report - TradingView
Alumis Inc. Reports Phase 2 and Phase 1 Clinical Data, Announces Merger Agreement with ACELYRIN, and Highlights 2024 Financial Results - Nasdaq
Alumis Doubles R&D Investment, Secures Game-Changing Merger Worth $737M - StockTitan
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - BioPharma Dive
Pliant Pops Poison Pill as Concentra Threat Looms - BioSpace
Acelyrin adopts rights plan in response to Tang Capital stake By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
Acelyrin stock in focus after poison pill (SLRN:NASDAQ) - Seeking Alpha
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell -March 13, 2025 at 08:09 am EDT - Marketscreener.com
Acelyrin adopts rights plan in response to Tang Capital stake - Investing.com India
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - The Manila Times
Acelyrin: Potential Buyout Led By Concentra Biosciences (NASDAQ:SLRN) - Seeking Alpha
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
New York State Common Retirement Fund Lowers Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin Inc (SLRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):